Geron halts Phase 3 IMpactMF trial after DMC futility call

An independent data monitoring committee told Geron the trial was unlikely to meet its overall survival primary endpoint in JAK inhibitor-refractory myelofibrosis.

Geron halts Phase 3 IMpactMF trial after DMC futility call

Geron Corporation has discontinued its Phase 3 IMpactMF trial of imetelstat in patients with relapsed or refractory myelofibrosis, following a recommendation from the trial's independent Data Monitoring Committee (DMC). The DMC concluded the study was unlikely to achieve its primary endpoint of overall survival, prompting the Nasdaq-listed company to halt the programme with immediate effect.

The trial had enrolled 327 patients with intermediate-2 or high-risk myelofibrosis who had previously failed a JAK inhibitor. Participants were randomised 2:1 in an open-label, controlled design comparing imetelstat, administered at 9.4 mg/kg intravenously every three weeks, against best available therapy. Geron said no new safety signals emerged from the data and that no additional safety monitoring is required, preserving the known imetelstat safety profile. Full data analysis is ongoing, with results to be presented to the scientific community at a future date.

A setback for imetelstat's expansion

The DMC recommendation is a significant clinical setback for Geron. Imetelstat, a telomerase inhibitor, is already approved in the United States and the European Union for lower-risk myelodysplastic syndromes (LR-MDS) under the brand name RYTELO, and IMpactMF had represented the company's main bid to extend its commercial reach into the larger myelofibrosis indication.

Joseph Eid, Executive Vice President, Research and Development and Chief Medical Officer, said: "Hematologic malignancies are complex diseases, with distinct biological characteristics and treatment challenges across patient populations. We remain committed to thoroughly evaluating the data, understanding what we can learn, and sharing insights that may help inform future research."

President and CEO Harout Semerjian sought to reassure investors, stressing that Geron retains a "growing commercial business" centred on RYTELO demand in the US and a strategy to broaden access for LR-MDS patients outside the US. The company did not provide updated guidance on its cash runway or the financial impact of winding down the trial.

Market context and competitive landscape

The myelofibrosis space is intensely competitive. Approved JAK inhibitors including ruxolitinib, fedratinib, and pacritinib occupy the frontline, and a number of companies are pursuing second-line options targeting patients who have progressed on or become intolerant to those agents. The failure of IMpactMF narrows the field of telomerase-directed approaches in this refractory setting, at least in the near term.

For Geron, the strategic pivot is now firmly toward consolidating RYTELO's position in LR-MDS, where the drug is commercialised and generating revenue. The myelofibrosis opportunity had been viewed by some analysts as a meaningful upside catalyst; its loss will sharpen scrutiny of the LR-MDS growth trajectory when the company next reports earnings. Investors will watch closely for any signal that Geron intends to pursue additional indications or combination studies to offset the setback and justify its longer-term hematology ambitions.